Logo image of ENSC

ENSYSCE BIOSCIENCES INC (ENSC) Stock Fundamental Analysis

NASDAQ:ENSC - Nasdaq - US2936024056 - Common Stock

8  +0.23 (+2.96%)

After market: 7.5256 -0.47 (-5.93%)

Fundamental Rating

3

Taking everything into account, ENSC scores 3 out of 10 in our fundamental rating. ENSC was compared to 572 industry peers in the Biotechnology industry. ENSC scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. ENSC is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year ENSC has reported negative net income.
ENSC had a negative operating cash flow in the past year.
In multiple years ENSC reported negative net income over the last 5 years.
In the past 5 years ENSC always reported negative operating cash flow.
ENSC Yearly Net Income VS EBIT VS OCF VS FCFENSC Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 0 -10M -20M

1.2 Ratios

ENSC's Return On Assets of -84.47% is on the low side compared to the rest of the industry. ENSC is outperformed by 70.62% of its industry peers.
Looking at the Return On Equity, with a value of -114.75%, ENSC is in line with its industry, outperforming 42.30% of the companies in the same industry.
Industry RankSector Rank
ROA -84.47%
ROE -114.75%
ROIC N/A
ROA(3y)-333.3%
ROA(5y)-193.26%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ENSC Yearly ROA, ROE, ROICENSC Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 0 5K 10K 15K

1.3 Margins

ENSC does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ENSC Yearly Profit, Operating, Gross MarginsENSC Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 -200 -400 -600 -800

More info and screens

6

2. Health

2.1 Basic Checks

ENSC does not have a ROIC to compare to the WACC, probably because it is not profitable.
ENSC has more shares outstanding than it did 1 year ago.
The number of shares outstanding for ENSC has been reduced compared to 5 years ago.
The debt/assets ratio for ENSC has been reduced compared to a year ago.
ENSC Yearly Shares OutstandingENSC Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 5M 10M 15M 20M
ENSC Yearly Total Debt VS Total AssetsENSC Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 50M 100M 150M 200M

2.2 Solvency

Based on the Altman-Z score of -17.82, we must say that ENSC is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of ENSC (-17.82) is worse than 85.84% of its industry peers.
There is no outstanding debt for ENSC. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -17.82
ROIC/WACCN/A
WACC9.14%
ENSC Yearly LT Debt VS Equity VS FCFENSC Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 0 50M 100M 150M

2.3 Liquidity

ENSC has a Current Ratio of 3.24. This indicates that ENSC is financially healthy and has no problem in meeting its short term obligations.
ENSC has a Current ratio of 3.24. This is in the lower half of the industry: ENSC underperforms 61.59% of its industry peers.
A Quick Ratio of 3.24 indicates that ENSC has no problem at all paying its short term obligations.
ENSC has a worse Quick ratio (3.24) than 60.00% of its industry peers.
Industry RankSector Rank
Current Ratio 3.24
Quick Ratio 3.24
ENSC Yearly Current Assets VS Current LiabilitesENSC Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 5M 10M 15M

More info and screens

5

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 90.66% over the past year.
Looking at the last year, ENSC shows a very strong growth in Revenue. The Revenue has grown by 40.36%.
EPS 1Y (TTM)90.66%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%108.05%
Revenue 1Y (TTM)40.36%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%685.29%

3.2 Future

The Earnings Per Share is expected to grow by 163.16% on average over the next years. This is a very strong growth
The Revenue is expected to grow by 157.05% on average over the next years. This is a very strong growth
EPS Next Y-139.6%
EPS Next 2Y-56.65%
EPS Next 3Y163.16%
EPS Next 5YN/A
Revenue Next Year107.5%
Revenue Next 2Y-41.42%
Revenue Next 3Y186.08%
Revenue Next 5Y157.05%

3.3 Evolution

ENSC Yearly Revenue VS EstimatesENSC Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 20M 40M 60M 80M
ENSC Yearly EPS VS EstimatesENSC Yearly EPS VS EstimatesYearly EPS VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 0 -500 -1K -1.5K

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for ENSC. In the last year negative earnings were reported.
Also next year ENSC is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ENSC Price Earnings VS Forward Price EarningsENSC Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ENSC Per share dataENSC EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 -5 -10

4.3 Compensation for Growth

ENSC's earnings are expected to grow with 163.16% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-56.65%
EPS Next 3Y163.16%

More info and screens

0

5. Dividend

5.1 Amount

ENSC does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ENSYSCE BIOSCIENCES INC

NASDAQ:ENSC (1/21/2025, 8:00:02 PM)

After market: 7.5256 -0.47 (-5.93%)

8

+0.23 (+2.96%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-12 2024-11-12/amc
Earnings (Next)N/A N/A
Inst Owners4.41%
Inst Owner Change0.13%
Ins Owners1.54%
Ins Owner Change0%
Market Cap7.92M
Analysts82.86
Price Target104.04 (1200.5%)
Short Float %N/A
Short Ratio0
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)83.98%
Min EPS beat(2)44.7%
Max EPS beat(2)123.26%
EPS beat(4)3
Avg EPS beat(4)38.42%
Min EPS beat(4)-54.38%
Max EPS beat(4)123.26%
EPS beat(8)7
Avg EPS beat(8)41.95%
EPS beat(12)9
Avg EPS beat(12)-139.01%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)600.1%
Min Revenue beat(2)-40.59%
Max Revenue beat(2)1240.78%
Revenue beat(4)2
Avg Revenue beat(4)300.74%
Min Revenue beat(4)-40.59%
Max Revenue beat(4)1240.78%
Revenue beat(8)2
Avg Revenue beat(8)138.2%
Revenue beat(12)3
Avg Revenue beat(12)80.28%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)1400%
PT rev (3m)1128.92%
EPS NQ rev (1m)0%
EPS NQ rev (3m)44.62%
EPS NY rev (1m)0%
EPS NY rev (3m)-770.63%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-15.25%
Revenue NY rev (1m)69.39%
Revenue NY rev (3m)295.24%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1.79
P/FCF N/A
P/OCF N/A
P/B 1.15
P/tB 1.15
EV/EBITDA N/A
EPS(TTM)-2.07
EYN/A
EPS(NY)-13
Fwd EYN/A
FCF(TTM)-8.62
FCFYN/A
OCF(TTM)-8.62
OCFYN/A
SpS4.47
BVpS6.98
TBVpS6.98
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -84.47%
ROE -114.75%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-333.3%
ROA(5y)-193.26%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.47
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.24
Quick Ratio 3.24
Altman-Z -17.82
F-Score4
WACC9.14%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)90.66%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%108.05%
EPS Next Y-139.6%
EPS Next 2Y-56.65%
EPS Next 3Y163.16%
EPS Next 5YN/A
Revenue 1Y (TTM)40.36%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%685.29%
Revenue Next Year107.5%
Revenue Next 2Y-41.42%
Revenue Next 3Y186.08%
Revenue Next 5Y157.05%
EBIT growth 1Y54.18%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-81.5%
EBIT Next 3Y-2.26%
EBIT Next 5Y31.23%
FCF growth 1Y53.49%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y53.49%
OCF growth 3YN/A
OCF growth 5YN/A